Delivery Order SPE2DB20D2104-SPE2DB25FMXHV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $28,970.38. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and represents a component of the company's broader pharmaceutical supply relationship with the federal government. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,781.60. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and was competitively awarded with no set-aside designation. The award is classified as a child contract, indicating it derives from a larger contract vehicle. AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count package) under a firm fixed-price contract valued at $1,722.16. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 tablets, valued at $5,141.86 under a firm fixed price contract. This delivery order represents a non-set-aside competitive award and is scheduled for completion by August 11, 2025. The products will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,216.14 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count package). This contract was executed under a firm fixed price arrangement with no set-aside designation, indicating it was awarded through competitive procurement. The delivery order is part of AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXHVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $4,380.23 and an ultimate completion date of August 11, 2025. This competitive, non-set-aside delivery order utilizes firm fixed price terms and represents a continuation of the federal pharmaceutical supply relationship between DLA and the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 through December 2026 that supports military healthcare procurement globally. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, supplies a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The Dapagliflozin order represents routine pharmaceutical fulfillment under this strategic vehicle, which DLA designed to provide flexible and comprehensive medical supply capabilities across multiple therapeutic domains to military and veteran healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/8/25 |